Gene therapy firms race forward amid cash crunch, setbacks

In July 2026, Forge Biologics and Restore Vision announced a strategic partnership aimed at advancing AAV-based gene therapies for inherited retinal diseases, specifically targeting retinitis pigmentosa with the RV-001 candidate. This collaboration leverages Forge's Columbus, Ohio manufacturing facility to optimize processes and support clinical development, reflecting a concerted effort to streamline production and accelerate therapeutic availability. Despite the inherent manufacturing complexities and regulatory hurdles unique to ophthalmic gene therapies, both companies express strong optimism about successfully navigating these challenges to bring RV-001 through clinical evaluation.

The partnership between Forge Biologics and Restore Vision extends beyond manufacturing to include comprehensive process optimization, small-scale development, GMP-compliant production, and logistics coordination, all designed to underpin Restore Vision's Phase I/II clinical trial in Japan. This multifaceted collaboration underscores the importance of integrated support systems in overcoming the technical and regulatory intricacies of gene therapy development, particularly in international trial settings, thereby enhancing the potential for timely and efficient clinical advancement.

Ocugen is pioneering a modifier gene therapy platform that adopts a gene-agnostic strategy to tackle a spectrum of inherited retinal diseases and blindness-related disorders by targeting the underlying disease biology across multiple gene networks. This innovative approach positions the company to address complex degenerative eye conditions beyond single-gene mutations, potentially broadening therapeutic impact.

In September 2026, Ocugen is set to unveil Phase 2 clinical trial data demonstrating the safety and efficacy of its subretinal OCU410 gene therapy for geographic atrophy, a progressive form of macular degeneration. Dr. Raj K. Maturi will present these encouraging findings at the Retina Society's Annual Scientific Meeting on September 24, marking a significant milestone in the company’s clinical progress against this challenging degenerative eye disease.

To amplify investor and industry engagement, Ocugen is strategically showcasing its gene therapy platform at several high-profile events throughout September 2026. CEO Dr. Shankar Musunuri will lead key presentations, including a fireside chat at the Citi 2026 Biopharma Back to School Conference on September 9 and a session at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, signaling the company’s commitment to transparency and leadership in advancing gene therapies for blindness.

Cirrus Therapeutics has successfully raised $14.7 million in expanded seed funding to propel its ocular immunology pipeline, focusing on preclinical AAV gene therapies targeting IRAK-M for dry age-related macular degeneration and geographic atrophy. Alongside its gene therapy efforts, the company is also advancing a next-generation retinal pigment epithelium cell therapy, aiming to bring its lead gene therapy candidate closer to clinical trials in the near term. This dual approach underscores Cirrus's commitment to addressing degenerative eye diseases through both genetic and cellular modalities.

Strategically expanding its footprint in Asia, Cirrus Therapeutics has established an R&D site in Singapore and forged collaborations with prominent institutions such as the Singapore Eye Research Institute, Duke-NUS Medical School, and A*STAR. This expansion enhances Cirrus's research and clinical development capabilities within the Asia-Pacific region, positioning the company to leverage regional expertise and partnerships to accelerate its ocular immunology programs. By embedding itself in this vibrant biotech hub, Cirrus is well-placed to advance its innovative therapies on a global scale.

By mid-2026, Ocugen faced mounting financial pressures, reporting a significant net loss of $44.1 million year-to-date, with a troubling $24.9 million loss in Q2 alone. Despite efforts to stabilize its finances, the company’s accumulated deficits and negative stockholders’ equity raised serious doubts about its ability to continue as a going concern within the next year, underscoring the precarious balance between advancing costly gene therapy development and maintaining fiscal health.

In response to these challenges, Ocugen secured $112.5 million through convertible senior notes and other financing activities, boosting its cash reserves to $100.1 million. However, this capital raise comes with strings attached: shareholder approval is required to convert these notes into stock, with a critical meeting scheduled for September 21, 2026, to authorize potential dilution. This move highlights the tension between immediate liquidity needs and long-term shareholder value, reflecting broader market challenges faced by gene therapy developers reliant on continuous funding amid uncertain clinical and commercial outcomes.